These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1497685)

  • 41. [Preliminary evaluation of early results of the treatment of epilepsy in children with delayed-action carbamazepine].
    Losiowski Z; Czochañska J; Zimak J
    Neurol Neurochir Pol; 1992; 26(4):571-2. PubMed ID: 1484585
    [No Abstract]   [Full Text] [Related]  

  • 42. [Evaluation of the biological availability of 2 carbamazepine preparations].
    Niedzielska K; Rosnowska M; Kuran W
    Neurol Neurochir Pol; 1986; 20(5):415-20. PubMed ID: 3295573
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carbamazepine dose-frequency requirement in children.
    Rylance GW; Moreland TA; Butcher GM
    Arch Dis Child; 1979 Jun; 54(6):454-8. PubMed ID: 475429
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bioavailability of four different pharmaceutical preparations of carbamazepine.
    Pynnönen S; Mäntylä R; Iisalo E
    Acta Pharmacol Toxicol (Copenh); 1978 Oct; 43(4):306-10. PubMed ID: 362821
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting the range of plasma carbamazepine concentrations in patients with epilepsy.
    Racine-Poon A; Dubois JP
    Stat Med; 1989 Nov; 8(11):1327-37. PubMed ID: 2609045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Overnight fall in the serum level of carbamazepine (author's transl)].
    Fröscher W; Eichelbaum M; Gugler R; Baur MP
    Nervenarzt; 1979 Mar; 50(3):171-8. PubMed ID: 571537
    [No Abstract]   [Full Text] [Related]  

  • 47. Time course of carbamazepine autoinduction. The VA Cooperative Study No.118 Group.
    Mikati MA; Browne TR; Collins JF
    Neurology; 1989 Apr; 39(4):592-4. PubMed ID: 2927687
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects.
    Riva R; Albani F; Ambrosetto G; Contin M; Cortelli P; Perucca E; Baruzzi A
    Epilepsia; 1984 Aug; 25(4):476-81. PubMed ID: 6540170
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients. Preliminary pharmacokinetic results.
    Loonen AJ; Toll PJ; Nijdam JR
    Pharm Weekbl Sci; 1989 Feb; 11(1):23-6. PubMed ID: 2710641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adverse effects from the circadian fluctuations of carbamazepine plasma levels.
    Blennow G
    Acta Paediatr Scand; 1983 May; 72(3):397-401. PubMed ID: 6880726
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rational use of generic psychotropic drugs.
    Carbon M; Correll CU
    CNS Drugs; 2013 May; 27(5):353-65. PubMed ID: 23620145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of generic substitution of anticonvulsants on the treatment of epilepsy.
    Richens A
    CNS Drugs; 1997 Aug; 8(2):124-33. PubMed ID: 23338217
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.
    Kesselheim AS; Stedman MR; Bubrick EJ; Gagne JJ; Misono AS; Lee JL; Brookhart MA; Avorn J; Shrank WH
    Drugs; 2010 Mar; 70(5):605-21. PubMed ID: 20329806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets.
    Tothfalusi L; Speidl S; Endrenyi L
    Br J Clin Pharmacol; 2008 Jan; 65(1):110-22. PubMed ID: 17711537
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparative evaluation of pharmacokinetics of conventional and slow-release carbamazepine formulation in newly treated patients of epilepsy: a random evaluation.
    Nag D; Garg RK; Agarwal A
    J Assoc Physicians India; 1998 Feb; 46(2):185-8. PubMed ID: 11273108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
    Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
    J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine.
    Miller AD; Krauss GL; Hamzeh FM
    Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of carbamazepine Divitabs and a normal carbamazepine preparation in psychiatric and oligophrenic patients.
    Nijdam JR; Doorschot CH; van Bavel LP; Loonen AJ
    Pharmacopsychiatry; 1992 May; 25(3):145-9. PubMed ID: 1635933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations.
    Wolf P; May T; Tiska G; Schreiber G
    Arzneimittelforschung; 1992 Mar; 42(3):284-8. PubMed ID: 1497685
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.